Aprio Wealth Management LLC Has $367,000 Position in IQVIA Holdings Inc. (NYSE:IQV)

Aprio Wealth Management LLC grew its position in IQVIA Holdings Inc. (NYSE:IQV) by 21.9% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,547 shares of the medical research company’s stock after buying an additional 278 shares during the quarter. Aprio Wealth Management LLC’s holdings in IQVIA were worth $367,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in IQV. Jennison Associates LLC grew its holdings in shares of IQVIA by 7.3% during the 1st quarter. Jennison Associates LLC now owns 140,914 shares of the medical research company’s stock valued at $35,636,000 after purchasing an additional 9,578 shares during the last quarter. Nomura Holdings Inc. bought a new stake in shares of IQVIA during the 4th quarter valued at approximately $857,000. PGGM Investments grew its holdings in shares of IQVIA by 55.8% during the 2nd quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock valued at $2,553,000 after purchasing an additional 4,326 shares during the last quarter. Fiduciary Alliance LLC bought a new stake in shares of IQVIA during the 1st quarter valued at approximately $1,864,000. Finally, SG Americas Securities LLC grew its holdings in shares of IQVIA by 80.1% during the 1st quarter. SG Americas Securities LLC now owns 45,787 shares of the medical research company’s stock valued at $11,579,000 after purchasing an additional 20,369 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently issued reports on IQV. Argus raised shares of IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Evercore ISI decreased their price target on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a report on Tuesday. JPMorgan Chase & Co. boosted their target price on shares of IQVIA from $260.00 to $288.00 and gave the stock an “overweight” rating in a report on Monday, August 5th. UBS Group boosted their target price on shares of IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. Finally, Robert W. Baird boosted their target price on shares of IQVIA from $251.00 to $256.00 and gave the stock a “neutral” rating in a report on Friday, September 20th. Five analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $266.67.

IQVIA Stock Up 0.6 %

IQVIA stock opened at $226.78 on Wednesday. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80. IQVIA Holdings Inc. has a 12-month low of $167.42 and a 12-month high of $261.73. The firm’s fifty day moving average is $240.50 and its 200 day moving average is $232.20. The company has a market capitalization of $41.34 billion, a PE ratio of 30.98, a PEG ratio of 2.18 and a beta of 1.49.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The firm had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.79 billion. During the same quarter in the prior year, the company posted $2.22 earnings per share. The business’s revenue was up 2.3% on a year-over-year basis. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 10.25 EPS for the current fiscal year.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 1.60% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.